Respiratory Syncytial Virus - A Drug Pipeline Analysis Report by Technavio

September 27, 2018

LONDON--(BUSINESS WIRE)--Sep 27, 2018--Technavio has announced their latest drug pipeline analysis report on the . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of the respiratory syncytial virus. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180927005948/en/

Technavio has published a new report on the drug development pipeline for the treatment of respiratory syncytial virus, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

Respiratory syncytial virus: An overview

Respiratory syncytial virus (RSV) is one of the most common diseases that affect children. RSV is one of the human pathogens in infants, young children, and the elderly. It also affects the people with an impaired immune system. Almost all children are exposed to RSV by the age of two. RSV causes common cold in most patients. In unguarded children, RSV can develop to either bronchiolitis or pneumonia or even both with increased chances of notable morbidity or death. Understanding how RSV interacts with its host is crucial to facilitate the development of safe and effective vaccines and therapeutic treatments.

RSV enters the body through the nose, eyes, or mouth and spreads easily through the air. A person can get infected if a person infected with RSV coughs or sneezes near him/her.

This report is available at a USD 1,000 discount for a limited time only:

Respiratory syncytial virus: Segmentation of pipeline molecules

Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with more than 23% of the pipeline molecules administered through this mode.

Between companies and institutions, companies led the drug development space for the treatment of the respiratory syncytial virus. Some of the key players include ABIVAX, Ablynx, CureVac, Enanta, and Gilead.

Looking for more information?

Some of the key topics covered in the report include:

1. Scope of the Report

2. Regulatory Framework

3. Drug Development Landscape

Drugs under development

4. Drug Development Strategies

Therapies employed Route of administration Therapeutic modality Mechanism of action

5. Recruitment Strategies

Geographical coverage Recruitment status Gender Age

6. Key Companies

Type of players Company overview

7. Discontinued and Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180927005948/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200




SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 09/27/2018 04:52 PM/DISC: 09/27/2018 04:52 PM


Update hourly